Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colorectal Neoplasms: early-phase trial registry
23 of 55 indexed Colorectal Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #254 of 28,707 conditions by registered trial count.
55 US clinical trials · 23 currently recruiting · #254 of 28,707 conditions by registered trial count
Colorectal Neoplasms: 55 US clinical trials tracked, 23 recruiting.
Colorectal Neoplasms is the subject of 55 registered US clinical trials on ClinicalTrials.gov, 23 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 31 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition colorectal-neoplasms
OPEN 23 | RECR 42% | LATE 9 | EARLY 31 | RANK #254 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Stress (42% recruiting · 153 trials)
Colorectal Neoplasms lists 23 open slots (42% of 55 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Colorectal Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Colorectal Neoplasms is recruiting above its size-band peers.
23 of 55 indexed trials (41.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Colorectal Neoplasms trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 7 of 55 trials (12.7%). 30 distinct sponsors appear on at least one study for this condition label.
-
Typical Colorectal Neoplasms enrolment sits around 268 participants.
Median target enrolment is 268 among the 55 trials that report a genuine target (sentinel values excluded). 16 of those (29.1%) plan for fewer than 100 participants.
-
Colorectal Neoplasms research is mostly interventional.
48 interventional and 7 observational studies make up this index (87.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
55 total, page 1 of 2
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
Dartmouth-Hitchcock Medical Center
NCT05612347
Early Detection of Advanced Adenomas and Colorectal Cancer
City of Hope Medical Center
NCT06342440
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
National Cancer Institute (NCI)
NCT01915225
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Janssen Research & Development
NCT06662786
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06131840
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
NCT07222800
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Janssen Research & Development
NCT06750094
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
NCT04956640
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
NCT06400472
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Eli Lilly and Company
NCT07114601
First in Human Study of AZD9592 in Solid Tumors
AstraZeneca
NCT05647122
Early Onset Colorectal Cancer Detection
City of Hope Medical Center
NCT06342401
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Seagen, a wholly owned subsidiary of Pfizer
NCT05253651
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Janssen Research & Development
NCT07107230
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
NCT06447662
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
Surgimab
NCT03659448
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Eli Lilly and Company
NCT07213791
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development
NCT06663319
A Study of DM002 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co.
NCT06751329
Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer
Memorial Sloan Kettering Cancer Center
NCT04812912
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT04222413
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
NCT07158164
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Cancer Institute (NCI)
NCT05286814
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Seattle Project Corporation
NCT05141721
S0820, Adenoma and Second Primary Prevention Trial
SWOG Cancer Research Network
NCT01349881
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT03485209
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai
NCT04008797
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
National Cancer Institute (NCI)
NCT02484404
My Best GI Eating Study
University of Michigan
NCT05396846
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT05358249
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05983133
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05571839
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
NCT06704724
Physical Activity Centers Empowerment
UNC Lineberger Comprehensive Cancer Center
NCT06411756
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06466187
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Cancer Institute (NCI)
NCT05185947
Effect of Patient Portal Messaging Before Mailing Fecal Immunochemical Testing Kit on Colorectal Cancer Screening Rates
University of California, Los Angeles
NCT05115916
Underwater Resection of Non-pedunculated Colorectal Lesions
VA Northern California Health Care System
NCT02889679
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
Wake Forest University Health Sciences
NCT03935282
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Merck Sharp & Dohme
NCT04776148
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
Pfizer
NCT00101686
Impact of Experience on Results With the Third Eye Retroscope
Avantis Medical Systems
NCT00969124
Study of Flat Polyp Detection Using New Narrow Band Imaging (NBI) Compared to White Light Colonoscopy - The FIND FLAT Colonoscopy Study
VA Palo Alto Health Care System
NCT01310699
Chromogranin A as Blood Marker in Cancer Patients
Brahms
NCT03817866
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
NCT02124148
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
City of Hope Medical Center
NCT06314971
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana
NCT03428958
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai
NCT05091346
A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer
National Cancer Institute (NCI)
NCT00001428
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
Bayer
NCT01289821
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 8 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Colorectal Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Colorectal Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Colorectal Neoplasms page
55 registered trials, 23 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 23 Colorectal Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Colorectal Neoplasms trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Neoplasms condition card totals 55 registered trials; most-linked intervention bevacizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.